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Peroxisome proliferator-activated receptor (PPARγ) has been shown to have a protective role in the nephron through its ability
to inhibit a transforming growth factor- (TGF-β) mediated ﬁbrotic response. In contrast, PPARγ was also shown to induce
a mesenchymal transformation in epithelial intestinal cells. A ﬁbrotic response in the collecting duct has only recently been
established; however, the entire collecting duct has not been fully examined. Inner medullary collecting duct cells (IMCD-K2)
and mouse cortical collecting duct cells (M1), representing the cortical and medullary collecting duct, were exposed to 5–10μM
troglitazone for 24 hours. Troglitazone resulted in an elongated morphology, 60% decreases in E-cadherin and β-catenin, a 35%
decrease in α-catenin, and a 1.5-fold increase in ﬁbronectin. These eﬀects were not reversed with PPARγ antagonists or aﬀected
with PPARγ overexpression. Our results indicate that troglitazone induced a mesenchymal-like transformation in M1 and IMCD-
K2 epithelial cells independently of PPARγ.
1.Introduction
PPARs are ligand-activated transcription factors that het-
erodimerize with an RXR receptor. There are currently three
cloned PPARs (α, γ,a n dβ/δ), all of which are expressed
in diﬀerent tissues at various levels and are involved in
numerous cellular events including metabolism, diﬀeren-
tiation, growth, apoptosis, and tumorigenesis [1–4]. The
glitazone receptor, PPARγ, is abundant in brown adipose
tissue, intestine, spleen, and kidney. Certain nonsteroidal
anti-inﬂammatory drugs (NSAIDs) and thiazolidinediones
(TZDs), of which troglitazone is a member, are synthetic
PPARγ ligands [5]. Natural ligands include 15-deoxy-
prostaglandin J2 (PGJ2), certain polyunsaturated fatty acids
(PUFAs) such as linoleic acid, and endogenous low-density
lipoprotein (LDL) particles.
In the kidney, PPARγ ligands have been shown to have
ap r o t e c t i v ee ﬀect in various segments of the nephron
including the glomerulus (podocytes and mesangial cells),
proximal tubule, and distal tubule. Although PPARγ expres-
sion is among the highest in the collecting duct (CD), its role
in the CD remains unclear. PPARγ activation by TZDs has
been shown to result in oedema through enhanced epithelial
sodium cotransporter (ENaC) activity in the CD [6]. These
eﬀects were blocked by amiloride, a CD-speciﬁc diuretic.
The deletion of PPARγ from the collecting duct, using
PPARγﬂox/ﬂox mice, was also successful in reversing the ﬂuid
retention. The full impact of PPARγ ligands in the collecting
duct requires further characterization as the potential renal
protective and antidiabetic eﬀects are promising. Whether
PPARγ is an antiﬁbrotic transcription factor is unclear as
there have been studies indicating an induction of ﬁbrotic
responsesbyPPARγ ligands.Anexampleofthiswasfoundin
the intestine where activation of PPARγ was shown to induce
a mesenchymal transition in epithelial intestinal cell line [7].
Epithelial cells form organized cell-cell adhesion junc-
tionspreventingmovementofindividualcellsandproducing
a tight epithelial surface. Mesenchymal cells, however, tend2 Journal of Biomedicine and Biotechnology
to be highly motile as they lack this level of organization. The
transformation of EMT is described as the process in which
epithelial cells that function as ion and ﬂuid transporters
losetheirepithelialpolarity,cellularadhesionmolecules,and
reorganize their actin cytoskeleton from a cortical bundle
formation that supported adhesion molecules into stress
ﬁbers containing de novo expressed α-smooth muscle actin
(α-SMA) that supports migration.
EMT has been described in the collecting duct where
TGF-β induced activation of Smad3 and ERK1/2 leading to a
mesenchymal morphology, increased vimentin and α-SMA,
andadecreaseinE-cadherinandβ-catenin[8].Expressionof
E-cadherinhasbeenshowntovaryinverselywithﬁbronectin
in several diseased states including a unilateral ureteral
obstruction(UTO)model,amodelwhichinvokesscarringin
thecollectingduct[9].Thisstudy,however,doesnotaccount
forafullrepresentationofthecollectingductasitfocusedon
the terminal section.
E-cadherin is an integral, Ca2+-dependent transmem-
brane adhesion protein that is generally localized at the
adheren junctions of epithelial cells and plays an important
role in the development and maintenance of renal epithelial
polarity. The intracellular domain of E-cadherin is bound to
β-catenin that is bound to α-catenin, which in turn links
the entire complex to the actin cytoskeleton. Unbound β-
catenin can also function as a component of the Wnt nuclear
signaling pathway acting as a coactivator of T-cell factor
(TCF)/lymphocyte enhancer factor (LEF) transcription fac-
tors [9, 10].
PPARγ has been shown to interact with members
of the cadherin-catenin cytoskeletal complex through the
functional peroxisome proliferator response element (PPRE)
described in E-cadherin [11], as well as its catenin-binding
domain (CDB) which interacts directly with the TEC/LEF
domain in β-catenin [10]. Studies have shown that PPARγ
activation induces proteasomal degradation of β-catenin as
well as a reduction in E-cadherin in several cell types, includ-
ing hepatocytes [12]. In normal cells, PPARγ can function
to suppress Wnt signaling by targeting phosphorylated β-
catenin to the proteasome through a process involving the
above-mentioned catenin-binding domain [1].
The overall purpose of this study is to clarify the mecha-
nisms by which TRO/PPARγ alters collecting duct structure
and function. We report that TGF-β was unable to initiate an
epithelial to mesenchymal transformation in the IMCD-K2
and M1 collecting duct cell lines. In contrast, Troglitazone
caused morphological changes, decreased E-cadherin, α-
catenin and β-catenin, and increased ﬁbronectin. These
eﬀects were not reversed with PPARγ antagonists or altered
by PPARγ overexpression.
2.MaterialsandMethods
2.1. Cell Culture. The IMCD-K2 cell line is derived from
the initial section of the IMCD of an SV40-transgenic
mouse. These were a generous gift from Dr. Bruce Stanton
(Dartmouth Medical School). IMCD-K2 cells were grown in
DMEM:F-12 (1:1) media supplemented with 10% FBS, 1%
ITS, 1% Penicillin-Streptomycin, 1% L-glutamine, and 5μM
dexamethasone and were maintained at 5% CO2 and 37◦C
during culture and treatment. The M-1 cells are a mouse
cortical collecting duct cell line (ATCC no. CRL-2038).M 1
cellsweregrownat37◦Cand5%CO2 inDMEM:F-12media
(1:1), pH 7.4, containing, 5% FBS, and 1% Pen-Strep.
2.2. Chemicals and Reagents. Troglitazone (Sigma) is a
synthetic PPARγ agonist and was used at 5μMa n d1 0μM.
Troglitazone is a well-studied synthetic PPARγ agonist. It
has high speciﬁcity for PPARγ as it does not activate the
PPARδ or PPARα isoforms at a concentration of 25mM
and higher. Troglitazone is a member of a class of antidi-
abetic drugs that are currently used to improve insulin
sensitivity in type 2 diabetics. GW9662 (Cayman Chemicals)
is a PPARγ antagonist that covalently modiﬁes Cys285
in PPARγ’s LBD. PPARγ antagonist (T0070907) (Cayman
Chemical) covalently modiﬁes Cys313 thereby modulating
PPARγ cofactor recruitment. Both antagonists were used
alongside Troglitazone at 10μM. PGJ2 (Cayman Chemical)
is an endogenous PPARγ agonist. All reagents were dissolved
inDMSOtotheirsuggestedstockconcentrations.Antibodies
for α-SMA, α-catenin, β-actin, β-catenin, ﬁbronectin, and E-
cadherin were obtained from Sigma-Aldrich (ON, Canada).
Anti-PPARγ was obtained from Santa Cruz Biotech (CA,
USA). AlexaFluor Phalloidin and DAPI were gifts from Dr.
Chris Kennedy (University of Ottawa).
2.3. Western Blot. Following stimulations, protein isolations
were performed using RIPA lysis buﬀer consisting of:
RIPA buﬀer, 10mM Na ﬂuoride, 1mM Na pyrophosphate,
100μM Na orthovanadate, 1:100 protease inhibitor cocktail
(Sigma), and 500μM PMSF. The solution was centrifuged
at 10,000 ×g for 10 minutes, and protein was quantiﬁed by
spectrophotometry using Bradford reagent and denatured
by boiling the samples at 95◦C for 5–10 minutes. Equal
amounts of lysates (50–100μg) were electrophoresed and
transferred onto a nitrocellulose membrane (Amersham).
The nitrocellulose membrane was blocked in 10% milk in
T B S / Tf o r1t o3h o u r s ,a n dap r i m a r ya n t i b o d yw a sa p p l i e d
directly to the milk and left overnight. Following three 20-
minute washes, the primary antibody solution was removed,
and the appropriate secondary antibody was applied in 10%
milk-TBS/T for 90 minutes, after which the membranes
were washed with TBS/T. The HRP-conjugated secondary
antibodies were developed with Pierce SuperSignal chemilu-
minescent reagent for 5 minutes and exposed to Kodak X-
Omat Blue XB-1 ﬁlm as well as digitally exposed using the
Alpha Innotech Fluorchem HD2 imaging system.
2.4. Immunoﬂuorescence. C e l l sw e r ep l a t e do nc o v e r s l i p s
and allowed to adhere overnight. The culture media was
replaced for 24 hours with serum-free DMEM:F-12 and
stimulated with TRO and GW9662 for an additional 24hrs.
The coverslips were washed with PBS to remove traces of
media and ﬁxed for 30 minutes at room temperature in 4%
paraformaldehyde or at −20◦C in a (1:1) methanol-acetone
solution. Excess ﬁxative was washed with PBS/Mg2+/Ca2+
for 2 × 5 minutes. Triton-X at 0.1% in PBS was used
for permeabilization for 30 minutes at room temperatureJournal of Biomedicine and Biotechnology 3
followed by 3 × 5-minute washes in PBS/Mg2+/Ca2+.T h e
coverslips were blocked in 5% BSA in 0.1% Triton-X in
PBS/Mg2+/Ca2+ for 1 hour prior to adding the antibody
of choice. All antibodies were diluted in 5% BSA in 0.1%
Triton-X in PBS/Mg2+/Ca2+. Cells were incubated with
Phalloidin-FITC for 1 hour at RT in the dark. Next, 3 × 5-
minute PBS/Mg2+/Ca2+ washes were performed prior to the
addition of the secondary, α-mouse FITC (Sigma) 1:300 for
90 minutes or DAPI (1:1000) for 15 minutes. The coverslips
were then mounted in Fluoromount G-mounting media
(Southern Biotech). Images were captured using the Zeiss
AxioCam of an Axioskop2 MOT Fluorescent microscope.
2.5. PPARγ Overexpression. pcDNA and pcDNA-PPARγ
vectors were obtained from Addgene as bacterial stabs.
The sizes of each insert were veriﬁed with XhoI/HindIII
digests. M1 cells were grown to 25% conﬂuence prior to
transfection.4μg of plasmid DNA was diluted to a volume of
150μLi nD M E Ma n d1 5μL of Polyfect Transfection Reagent
(Qiagen)wasaddedtothesolution.Thesuspensionwasthen
incubated at room temperature for 10 minutes, mixed with
1mLofculturemediacontaining0.1%ampicillin,andadded
to the culture plate. This was repeated 48 hours later for the
ﬁnal 24 hours of the 72 hours transfection period.
2.6. Statistics. GraphPad Prism v4.03 was used to plot and
analyse the data collected. Values are expressed as means ±
standard error of the mean (S.E.M.). An unpaired t-test
was used to assess statistical signiﬁcance between selected
experimental groups. A one-sample t-test was performed
against a hypothetical value of 1.0 for all groups as the values
r e p r e s e n t e df o l dc o n t r o l sw h e r et h ec o n t r o lg r o u pa l lh a d
values of 1.0. Statistical analysis for multiple comparisons
wasdoneusingone-wayANOVAcorrectedwithBonferroni’s
posttest. A P value ≤ 0.05 was regarded as statistically
signiﬁcant.
3. Results
3.1. TRO Induces Morphological Changes in M1 Cells. The
presence of PPARγ in both the M1 and IMCD-K2 cell lines
was veriﬁed through Western blot and RT-PCR (Figure 1)
with PPARγ being successfully overexpressed in M1 cells
as seen in Figure 1(a).T h eg e n e r a le ﬀects of TZDs in the
kidney have been protective; however, the treatment of
M1 cells with TRO resulted in a decrease in cell-to-cell
contact, disorganization of the F-actin cytoskeleton ﬁlament
network, and a less rounded, elongated spindle-like shape
at 5μMa n d1 0 μM, visualized through FITC-conjugated
Phalloidin(Figure 2).Thesemorphologicalchangeswerenot
attenuated by the PPARγ antagonist GW9662 at 10μMw i t h
the same order of disorganization and cell elongation being
observed after cotreatment in Figures 2(d) and 2(f).
3.2. Troglitazone Induces Cytoskeleton Reorganization in the
IMCD-K2 and M1 Collecting Duct Cell Lines. Along with
the aforementioned morphological changes, treatment of
IMCD-K2 and M1 cells with TRO resulted in a decrease
IMCD-K2     Cortex Medulla
(a)
M1                        pcDNA
DMSO
pcDNA-PPARγ
TRO DMSO TRO DMSO TRO
(b)
L p33   p46    p58     ctr L p33   p46    p58    ctr
−RT
(c)
Figure 1:PPARγ ispresentintheIMCD-K2andM1collectingduct
cell lines. (a) Western blot analysis of PPARγ detected a band at
67kDa in IMCDK2 cells, also shown in mouse cortex and medulla
lysates used as a positive control. (b) In M1 cells, endogenous
PPARγ levels as well as those of the pcDNA plasmid control and
pcDNA-PPARγ overexpression samples are shown, included for
each are samples treated for 24 hours with DMSO (vehicle) or
10μM troglitazone (TRO). (c) In diﬀerent passages of M1 cells
(ctr, P33, 46, and 48), RT-PCR analysis produced a 400bp product
corresponding to PPARγ detected on 1% agarose gel. The (RT-)
samples were used as a negative control. Lanes identiﬁed as L
contain DNA ladder.
in several epithelial adhesion markers. Figure 3 shows the
analysis of α-smooth muscle actin (α-SMA) in M1 cells
and vascular smooth muscle cells (VSMC, positive control).
As seen, α-SMA was not detectable in M1 cells even upon
TRO stimulation, whereas a strong signal was obtained by
Western blotting and immunoﬂuorescence in VSMC. By
immunoﬂuorescence, very weak staining for α-SMA was
observed in image B only upon a prolonged exposure up to
500ms, conﬁrming the minimal TRO eﬀect. This response
was not strong enough for detection by Western blot, even in
100μg of lysate. In comparison, Figures 4(a) and 7(a) show
a clear decrease in E-cadherin and increase in the intensity
of ﬁbronectin staining through immunoﬂuorescence in
response to TRO. Figures 4(b) and 4(c) show a 60% drop in
E-cadherin with TRO in M1 and IMCD-K2 cells. Treatment
with a lower dose of TRO resulted in a 30% drop in E-
cadherin. The same trend is shown in Figure 5 with a 60%
reduction in β-catenin levels after 24-hour TRO treatment,
and a 30% reduction in α-catenin (Figure 6). Conversely,
an upregulation of ﬁbronectin was obtained in response to
24-hour TRO (Figures 7(b) and 7(c)), near 2-fold in M1
cells,and1.5-foldinIMCD-K2cells.Incomparison,Figure 8
illustrates the response of M1 cells to PGJ2. As shown,
24-hour treatment with 0.5μMP G J 2 increased E-cadherin
and ﬁbronectin levels to 1.5–2-fold of control. A numerical
increase in β-catenin was also observed.4 Journal of Biomedicine and Biotechnology
(a) (b) (c)
(d) (e) (f)
Figure 2: Troglitazone induces morphological changes in M1 cells independent of PPARγ. Images of F-actin ﬁlaments stained with FITC-
conjugated phalloidin are shown, in M1 cells stimulated for 24 hours with (a) DMSO (vehicle), (b) 10μM GW9662 (PPARγ antagonist), (c)
5μM troglitazone (TRO), (d) GW9662 and 5μMT R O ,( e )1 0μM TRO, and (f) GW9662 and 10μM TRO. Magniﬁcation 100x.
3.3. TRO-Mediated Eﬀects in the M1 Collecting Duct Cell Line
Are PPARγ Independent. TZDs are known to induce several
PPARγ-independent eﬀects. In our study PPARγ antago-
nists GW9662 and T0070907 had no eﬀect on E-cadherin
(Figure 4(d)), β-catenin (Figure 5(c)), or ﬁbronectin (data
not shown). However, as shown in Figure 6, T0070907
resulted in a further 2-fold reduction in α-catenin levels, but
this was not statistically signiﬁcant. The overexpression of
PPARγinM1cellswasperformedtoseewhetheranenhance-
ment of the abovementioned eﬀects could be observed.
However, PPARγ overexpression did not signiﬁcantly change
the 50% decrease in E-cadherin in nontransfected M1 cells
compared to cells transfected with the pcDNA plasmid
control and the pcDNA-PPARγ vector insert (Figure 4(e)).
As seen in Figure 7(d) the 1.5-fold increase in ﬁbronectin
in nontransfected and plasmid control transfected cells was
not increased with PPARγ overexpression in pcDNA-PPARγ
transfected cells, instead yielding a modest 1.3-fold increase
in ﬁbronectin, lower than in nontransfected cells. Taken
together these results portray a system in which PPARγ does
not mediate TRO responses in collecting duct cells.
It should also be noted that the transformation of the
epithelialCDcelllinesviaacytotoxicresponseisunlikely.An
inhibition of growth along with p38 activation was described
in a previous study; however, no oxidative stress (ROS
generation) or cell death (cleaved caspase-3 expression) were
observed [13]. The reduction in cell number seen with TRO
compared to control can be primarily attributed to the
aforementioneddecreaseinproliferation.TROisalsoknown
to drop pH levels [14]; however, we did not observe any
signiﬁcant levels of acidosis in our cell culture media in a
48hr period.
4. Discussion
4.1. PPARγ in the Collecting Duct. PPARγ has previously
been detected in vivo in the medullary and cortical collecting
duct [13, 15] and was present in both IMCD-K2 andJournal of Biomedicine and Biotechnology 5
(a) (b)
(d) (c)
DMSO M1 + TRO V
α-SMA
β-actin
Figure 3: Troglitazone does not induce α-SMA expression in M1 cells. In the upper panel, α-smooth muscle actin (α-SMA) was assessed
by Western blotting in 100μg lysates from M1 cells treated with DMSO, conﬁrming the absence of α-SMA, vascular smooth muscle cells
(V) were used as a positive control, and 4 lanes of M1 cells treated with 10μM troglitazone (TRO) for 24 hours. In the lower panel, α-SMA
was assessed by immunoﬂuorescence. Images are shown of M1 cells stimulated with (a) DMSO and (b) 10μM troglitazone (TRO) for 24
hours, (c) antimouse FITC conjugated secondary as a negative control, and (d) vascular smooth muscle cells were used as a positive control.
Magniﬁcation 100x.
M1 cells in our study. To our knowledge the only other
studies on PPARγ and the collecting duct indicate that
it may be involved in sodium and ﬂuid balance, as seen
with the PPARγ knockout model reversing the oedemic
eﬀects resulting from TZD treatment [6, 16]. The use of
PPARγ agonists, speciﬁcally TZDs, on the other hand, has
raised interest in several ﬁelds of research due to their
potential antiﬁbrotic and antitumorigenic eﬀects. Troglita-
zone has been shown to suppress TGF-β-induced SMAD2/3
phosphorylation, thereby inhibiting EMT in human retinal
pigment epithelial cells independent of PPARγ [17]. It has
also been suggested that the antiproliferative eﬀects of TZDs
in cancer cells are also independent of PPARγ activation as
TZD analogs, unable to activate PPARγ, retain the ability
to induce apoptosis at an equal potency in several cancer
cell lines. Nonetheless, there is an emerging view that
some antitumorigenic eﬀectsare partially PPARγ dependent,
whereas most are independent of the receptor [1, 18].
In our studies PPARγ was successfully overexpressed
in M1 cells. The increased PPARγ levels did not appear
to alter cell morphology alone; however, stimulation with
TRO in over-expressed cells resulted in a similar phenotype
as in nontransfected M1 cells. Generally, PPARγ overex-
pression alone is suﬃcient to induce a cellular response
without the use of an agonist as seen in pancreatic islets
where overexpression of PPARγ protein suppressed insulin
secretion induced by stimulatory concentrations of glucose
[19, 20]. This was also seen in rat livers where PPARγ
was over-expressed using an additional adenoviral vector
(AdPPARγ), resulting in signiﬁcantly lower levels of ﬁbrosis
compared to controls [21]. Troglitazone has been shown
to act through both PPAR-dependent and -independent
mechanisms in epithelial cells. For instance, in porcine renal
epithelial tubules, TZDs can modulate the pathways inﬂu-
encing glucose and glutamine metabolism, as well as cellular
acidosis favoring reduced plasma glucose in vivo [14, 22].
Thisalterationincellularacidosisandglutaminemetabolism
was veriﬁed in pH-sensitive lung carcinoma cells where
TZD-dependent PPARγ activation was veriﬁed; however, the
primary eﬀects of the study were still independent of this
activation, instead involving PKC/ERK. The task remains
to decipher which eﬀects obtained with TZDs are PPARγ6 Journal of Biomedicine and Biotechnology
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Figure 4: Troglitazone attenuates E-cadherin expression in IMCD-K2 and M1 cells. In (a) E-cadherin is detected by immunoﬂuorescence
in M1 cells stimulated with DMSO (vehicle, upper) and 10μM troglitazone (lower) for 24 hours (magniﬁcation 100x). In (b) IMCD-K2
and M1 cells were treated with DMSO (vehicle) or troglitazone (TRO), and a representative Western blot is shown for E-cadherin (upper
bands) and corresponding β-actin (lower bands). In (c) the corresponding densitometric analysis is shown with data presented as mean ±
S.E.M. P ≤ 0.05 (∗). In (d) a densitometric analysis of E-cadherin is shown for M1 cells treated with 10μM TRO in the presence or absence
of the PPARγ antagonists GW9662 and T0070907. In (e) the densitometric analysis is shown for E-cadherin in M1 cells treated with DMSO
or 10μM TRO with endogenous PPARγ as well as those expressing the control pcDNA plasmid and pcDNA-PPARγ overexpression. Data
presented as mean ± S.E.M. P ≤ 0.05 (∗).
mediated and how they are interconnected with the PPARγ-
independent pathways to fully understand how these drugs
operate.
4.2. TGF-β and EMT in IMCD-K2 and M1 Cells. TGF-β was
unable to induce EMT in either cell line. This was surprising
as the IMCD-3 cell line, representing the terminal section of
the inner medulla has recently been shown to undergo EMT
uponstimulationwithTGF-β.Althoughourstimulationwas
extended to 96hrs, the high levels of E-cadherin and β-
catenin may have protected the tight junctions, requiring a
longer time point to achieve the initial disruptions in cell
contact required to initiate the expression of mesenchymal
markers. The enhanced growth rate of the immortalized cell
lines may have also contributed to the lack of a response.
Both TGF-β receptors as well as endogenous cytokine haveJournal of Biomedicine and Biotechnology 7
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Figure 5: Troglitazone attenuates β-catenin expression in IMCD-
K2 and M1 cells. IMCD-K2, and M1 cells were treated with DMSO
(vehicle) or troglitazone (TRO), and in (a) a representative Western
blot is shown for β-catenin and corresponding β-actin. In (b) the
corresponding densitometric analysis is shown with data presented
as mean ± S.E.M. P ≤ 0.05 (∗). In (c) a densitometric analysis
of β-catenin is shown for M1 cells treated with 10μMT R Oi n
the presence or absence of the PPARγ antagonists GW9662 and
T0070907.
been previously characterized in both cell lines [23, 24].
The inability to induce EMT prevented a full assessment
of whether PPARγ activation could have reversed these
eﬀects, which would have conﬁrmed a protective role for the
transcription factor in collecting duct cells.
4.3. Troglitazone and Cell Morphology. TRO caused a loss in
cell-to-cell contact and an elongated spindle-like phenotype
in a percentage of the treated cell population. The changes in
cell shape appear to be PPARγ independent as GW9662 did
not restore normal morphology or any cell-to-cell contact.
Additionally the agonist may have resulted in a further
disruption of cell integrity with TRO cotreatment. TRO may
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β-actin
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Figure 6: Troglitazone attenuates α-catenin in M1 cells. M1 cells
were treated with 10μM troglitazone (Tro) in the presence or
absence of the PPARγ antagonist T0070907. Western blot was
performed for α-catenin, and the results were normalized to β-
actin. (a) A representative blot is shown, and (b) the corresponding
densitometric analysis. Data presented as mean ± S.E.M. P ≤ 0.05
(∗).
be acting through both PPARγ-dependent and -independent
pathways in inducing the aforementioned changes in mor-
phology; however, with no partial reversal upon antagonism,
it is more likely that a PPARγ-independent pathway is able to
fulﬁll the necessary steps to obtain the phenotype observed.
PKC/Akt and MAP kinase activation may be involved as
TZDs have been shown to enhance PKC/Akt phospho-
rylation in both diabetic and nondiabetic rats and MAP
kinase activation is a well-characterized PPARγ-independent
response toTZDs[10]. This elongatedphenotype wasabsent
in populations that were able to reach conﬂuence. This
generally occurred if cells were stimulated with TRO at a
conﬂuence greater than 75%. Even with an inhibition in
growth, highly populated plates were able to proliferate in
c l o s ep r o x i m i t y .T R Od o e sn o ta p p e a rt ob ea b l et oa l t e r
morphology and initiate cell-to-cell contact disruption in
conﬂuent layers of IMCD-K2 and M1 cells. Similarly, intact
tubular epithelial layers do not undergo EMT upon TGF-β
stimulation either; however, loss of epithelial integrity (sub-
conﬂuence, wounding, and contact disassembly by Ca2+
removal) restores the ability of the monolayer to undergo
a mesenchymal transformation [25, 26]. This suggests that
there may be a similar phenomenon observed in our
study, with Troglitazone requiring a disruption in the cell
monolayer in order to induce the morphological changes
characterized.
4.4. Troglitazone and the ECM/Cytoskeleton. TRO induced
decreases in epithelial adhesion markers such as E-cadherin,8 Journal of Biomedicine and Biotechnology
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Figure 7: Troglitazone increases ﬁbronectin expression in IMCD-K2 and M1 cells. In (a) ﬁbronectin is detected by immunoﬂuorescence in
M1 cells stimulated with DMSO (vehicle, upper) and 10μM troglitazone (lower) for 24 hours (magniﬁcation 100x). In (b) IMCD-K2 and
M1 cells were treated with DMSO (vehicle) or troglitazone (TRO), and a representative Western blot is shown for ﬁbronectin (upper bands)
and corresponding β-actin (lower bands). In (c) the corresponding densitometric analysis is shown with data presented as mean ± S.E.M.
P ≤ 0.05 (∗). In (d) the densitometric analysis is shown for ﬁbronectin in M1 cells treated with DMSO or 10μM TRO with endogenous
PPARγ aswellasthoseexpressingthecontrolpcDNAplasmidandpcDNA-PPARγ overexpression.Datapresentedasmean ±S.E.M.P ≤ 0.05
(∗).
α-catenin, and β-catenin. TRO also caused an increase in
ﬁbronectin protein but did not trigger de novo α-SMA
expression, the hallmark of myoﬁbroblast generation. PGJ2
on the other hand increased E-cadherin, β-catenin, and
ﬁbronectin levels. This suggests that PPARγ activation in
vivo,a sP G J 2 is a supposed endogenous ligand of PPARγ,
may counteract the decreases in epithelial markers observed
in vitro with a synthetic ligand. These inconsistencies among
PPARγ ligands are mirrored in MCF-7 breast cancer cells
where conjugated linoleic acid, which acts as a PPARγ
agonist, also caused an upregulation and redistribution of
β-catenin and E-cadherin [27]. E-cadherin has been shown
to have a functional PPRE [11] suggesting that PPARγ
stimulation may result in an increase in E-cadherin levels.
Although the PGJ2 and TRO results contradict one another,
TRO stimulation may still involve a PPAR response element
since a PPARγ co-repressor complex could have bound
to E-cadherin’s PPRE, preventing further transcription and
thereby translation of the E-cadherin protein. A core func-
tion of p120-catenin is to regulate cadherin stability and
turnover by controlling cadherin entry into the degradative
endocytic pathways [1, 28]. The decrease in protein levels
could have been due to the prevention of E-cadherin
turnover and enhanced degradation. A closer look at p120-
catenin would clarify whether TRO’s eﬀects on E-cadherin
were secondary, preventing the regeneration of E-cadherin
protein, as opposed to causing the direct degradation of the
adheren marker.
Nonetheless, the decrease in E-cadherin in our study
occurs independently of PPARγ. The PPARγ antagonists
T0070907 and GW9662 did not reverse the decrease
observed. Overexpression of PPARγ did not alter the drop
in E-cadherin levels upon TRO stimulation either. The
opposing eﬀects of the two agonists, TRO and PGJ2,c r e a t e
another argument that the eﬀects of at least one of the
ligands are PPARγ independent. Another explanation is that
one ligand activates PPARγ at a higher capacity than the
other as this paradox has been shown to induce opposing
eﬀects in breast cancer tissue, depending on the magnitude
of PPARγ activation in terms of cellular proliferation,Journal of Biomedicine and Biotechnology 9
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Figure 8: PGJ2 increases ECM-cytoskeleton proteins in M1 cells.
M1 cells were treated with 0.5μMP G J 2 for 24 hours. Western blot
was performed for E-cadherin, β-catenin, and Fibronectin. (a) The
results were normalized to β-actin (n = 4) and (b) a densitometric
analysis is shown. Data presented as mean ± S.E.M. P ≤ 0.05 (∗).
diﬀerentiation, and apoptosis of cancer cells and tumors
[1]. For example, lower concentrations increased cellular
proliferation, whereas higher concentrations blocked cell
growth.
It should be noted that the 50% reduction in β-catenin
may have not only led to the destabilization of adheren
junctions and loss of cell-to-cell contact but also to decreases
in β-catenin activity as an LEF/TCF transcription factor,
possibly accounting for some of the other eﬀects observed
upon TRO stimulation. Whether any one eﬀect can be
directly linked to catenin signaling would require a full
restoration of β-catenin levels. TRO also caused a decrease
in α-catenin in M1 cells. This decrease was not reversed
by T0070907 suggesting the degradation of α-catenin to
be independent of PPARγ activation as well. Generally α-
catenin is thought of as a static link between the cadherin-
catenin chain and actin cytoskeleton; however, new roles
for α-catenin are being described as α-catenin has been
shown to exist as a monomer or a dimer with monomeric
α-catenin binding more strongly to E-cadherin-β-catenin
and the dimer preferentially binding to actin ﬁlaments [29].
Determining the proportion of monomeric to dimerized α-
catenin aﬀected by TRO stimulation may shed light on the
local regulation of actin assembly and organization at sites of
cadherin-mediated cell-cell adhesion.
Fibronectin was upregulated by TRO and PGJ2.I na
previous study we showed that lower concentrations of TRO
had no eﬀe c to nﬁ b r o n e c t i ni nc o l l e c t i n gd u c tc e l l s[ 13].
This provides a further argument for the concentration
dependence of TRO actions though the eﬀect of ﬁbronectin
seems to be mainly PPARγ independent (no eﬀect of PPARγ
antagonism or overexpression). Generally TZDs have been
shown to reverse ﬁbronectin expression in diseased states,
as in human lung carcinoma cells [3], in human cortical
ﬁbroblasts [30], in TGF-β-treated glomerular mesangial cells
[31], and in diabetic mice [32]. Nonetheless, the complex
nature and inconsistencies of PPARγ activation and function
in terms of its ligands are seen throughout the literature. An
inverse relation between the adhesion molecule E-cadherin
and the matrix protein ﬁbronectin has been established
in many diseased states, a trend observed in this study
suggesting that the collecting duct may be altered upon
stimulation with Troglitazone.
5. Conclusion
PPARγ is present in the collecting duct; however, the use of
TRO,apotentsyntheticligand,resultedinstructuralchanges
independent of its target receptor. These eﬀects were not
replicated with the use of PGJ2,ap r o p o s e de n d o g e n o u s
PPARγ ligand. PPARγ overexpression did not accentuate any
of the eﬀects obtained from stimulation with TRO. Taken
together the data suggest that TRO can alter ECM and
cytoskeletal marker expression in the CD leading to a partial
epithelial to mesenchymal-like transformation, independent
of PPARγ. The beneﬁcial eﬀects of PPARγ ligands in other
diseased systems highlight the relevance of this study and
underline the importance of fully understanding the eﬀects
of these drugs to improve their use and speciﬁcity.
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